Cemsidomide (CFT7455) is a highly potent and selective degarder of IKZF1/3 with cereblon binding IC50 of 0.4 nM and picomolar DC50.
Treatment of the KiJK cell line of anaplastic large cell lymphoma (ALCL) with CFT7455 for 6 hours led to an 89% reduction in IKZF1 protein levels.
CFT7455 demonstrated potent antiproliferative activity across a panel of NHL cell lines with MYC, BCL2, and/or BCL6 translocations or rearrangements.
CFT7455 is an orally bioavailable.
CFT7455 achieved improved in vivo potency and efficacy, including deeper and more durable tumor regressions in models of ALCL, diffuse large B-cell lymphoma (DLBCL) and MCL in xenograft models.
